Traws Pharma tivoxavir marboxil shows 100% survival in H5N1 rodent model; Phase 1 PK positive

Traws Pharma, Inc.

100% of TXM-treated mice survived lethal H5N1 challenge; all untreated controls died by study day 6.
Single 240 mg dose maintained plasma levels at EC90 for ~25 days; well tolerated up to 480 mg in Phase 1.
TXM exhibited sub-nanomolar EC50 against circulating 2022-2023 H5N1 strains and baloxavir-resistant viruses.
Investor call scheduled for March 31, 2025 at 10:00 AM ET to review antiviral programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.